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ABSTRACT 
 
Purpose: Aim is to evaluate the effectiveness of two different dosing regimen of human recombinant 
erythropoietin (rHuEpo) for preoperative autologous blood collection in patients undergoing hip arthroplasty.  
Methods: Prospective randomized trial where erythropoietin was administered intravenously;15000IU twice a 
week or 30000IU once a week (total of 90000IU)), combined with fero II sulfat peroraly and compared to 
administration of only fero II sulfat.  
Results: Although different dosing regimen of the same rHuEpo administration during  preoperative autologous 
blood donation have similar effect on collecting of two units of autologous blood, preoperative haemoglobin 
level and perioperative allogenic blood transfusion, once weekly dose regimen of rHuEpo was more convenient 
(although not statistically significant) for patients.  
Conclusion: We suggest more practical and comfortable but still very effective therapeutic regimen with single 
weekly intravenous administration of recombinant human erythropoietin (for patients scheduled for THA). 
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INTRODUCTION 
Patients undergoing total hip arthroplasty (THA) with baseline haemoglobin level of ≤ 130 g/L are usually 
unable to donate sufficient autologous blood volume to satisfy their transfusion requirements during and after the 
surgery. More than 50% of such patients require additional allogenic blood transfusions [1,2]. The goal of 
preoperative administration of recombinant human erythropoietin (rHuEpo) is to increase erythropoiesis in 
patients who are donating blood for autologous use and therefore decrease the need for allogenic transfusions 
[3,4]. Previous reports found that the pharmacological response to erythropoietin therapy is a function of dose 
and administration regimen and that repeated administration of rHuEpo is more effective in stimulating 
reticulocyte response than single-dose administration of the same total amount of rHuEpo[5]. Several studies 
suggest that if rHuEpo is administered subcutaneously rather than intravenously, a lower dose may be sufficient 
to maintain the haematocrit at a given level [6]. But, over the last twenty years researches recorded cases where 
patients developed neutralizing anti-erythropoietin antibodies, a rare complication after usage of rHuEpo to 
increase red-cell production, in patients with the anaemia
 
because of chronic renal failure.  Such antibodies can 
cause pure red-cell
 
aplasia [7]. The occurrence of antibody-mediated
 
pure red-cell aplasia was mostly related to 
the
 
subcutaneous administration of human recombinant erythropoietin [8,9]. The optimal dose, interval and route 
of administration for rHuEpo are yet to be established. 
The aim of this study is to evaluate the effectiveness of two different dosing regimen of rHuEpo administered 
intravenously to avoid all possible complications of subcutaneous administration (15000 IU of rHuEpo 
intravenously twice a week (total of 90000IU) or 30000 IU of rHuEpo intravenously once a week (total of 90000 
IU)), combined with fero II sulfat peroraly and compared to administration of only fero II sulfat peroraly, for 
collecting of two units of preoperative autologous blood and therefore reducing the need for allogenic blood 
transfusions after primary THA. 
 
PATIENTS AND METHODS 
Patients 
The study included 93 patients between 60 and 80 years of age who were scheduled for primary THA due to 
osteoarthritis. All patients who were able to donate autologous blood preoperatively with haemoglobin level 
between 105 and 130 g/L were suitable for the study. Patients were enrolled in the study after giving informed 
consent in accordance with the ethical committee of the hospital. Exclusion criteria were: history of bleeding 
disorder, history of seizures or uncontrolled hypertension, history of deep vein thrombosis, gastrointestinal 
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bleeding within 6 month before the surgery, malignancy, acute or chronic infection and consumption of 
cytostatic or immunosuppressant drugs. Iron was given orally in all patients as ferrous-II sulphate (3x 65 mg 
elementary iron) during the study, starting one week before the first autologous blood donation. THA in all 
patients was performed by senior authors using direct lateral approach. The human recombinant erythropoietin 
beta (Recormon
®
) used in the study was provided by F Hofmann - La Roche, Basel, Switzerland. For all patients 
routine premedication  included midasolam per os (0,1 mg/kg) 1 hour before the induction of anaesthesia and 
500mL of Ringer's solution before they were positioned upright for the induction of spinal anaesthesia at level of 
either L3/L4 or L2/L3 via midline approach. An isobaric solution of levobupivacain (3,0 – 3,5 mL)  were 
administered with 25 or 27G pencil-point needle. 
Study design 
Patients were randomly assigned in three groups: 30 patients received 15000 IU (average 200IU/kg) of rHuEpo 
intravenously twice a week (on 17
th
, 13
th
, 10
th
, 6
th
, 3
rd
 day preoperatively, and 2nd day postoperatively), and iron 
peroraly (group I); 31 patient received 30000 IU IU (average 400IU/kg) of rHuEpo intravenously once a week 
(on 17
th
, 10
th
 and 3
rd
 day preoperatively), and iron peroraly (group II); 32 patients received only iron peroraly 
(group III). Donation of 12% of total blood volume was performed at 10
th
 and 3
rd
 preoperative day. The 
minimum haemoglobin level (Hb) for donation was 110 g/L, according to current European guidelines for 
preoperative autologous donation[10]. The pre-study evaluation included thorough medical history and physical 
examination. Pre-study laboratory tests included complete blood count, reticulocyte count, serum chemistry 
studies, urin analysis, serum iron, TIBC, transferin saturation, and serum ferritin. At the time of each injection of 
rHuEpo, (17
th
 ,13
th
 ,10
th
 , 6
th
  and 3
rd
  preoperative day, for group I, and 17
th
 , 10
th
 , and 3
rd
 preoperative day, for 
group II and group III, respectively, vital signs, hematologic values (including reticulocytes) and serum 
chemistry (potassium) were assessed. If the Hb level was greater than 150 g/L erythropoietin beta was not 
administered, if the Hb level was less than 110 g/L, autologous blood was not donated. Adverse events, blood 
loss and transfusion data were collected for all patients by anaesthesiologist. The criteria for perioperative 
transfusion  (both autologous and allogenic) included haemoglobin level ≤80 g/L, and/or clinical symptoms of 
anaemia (increased heart rate or lower blood pressures despite an intravenous fluid bolus). All patients received 
the same protocol for deep venous thrombosis prophylaxis with low-molecular-weight heparin, and cefazolin (1g 
iv) was administered 60min before procedure for perioperative infection prophylaxis. In all patients reinfusion 
drains were used. The reinfusion drains (for cell salvage) were used in the immediate postoperative period in the 
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recovery room (first 6 hours), and were later converted to standard Hemovac drains. All drains were removed 48 
hours after arthroplasty. 
  
Laboratory studies 
Samples were obtained on 17
th
, 13
th
, 10
th
, and 3
rd
 day preoperatively, in group I and II before each injection of 
rHuEpo, and in group III immediately before donation of autologous blood. Blood was taken on the day of 
surgery: 2 hours preoperatively and 6 hours postoperatively, and on several postoperative days (1
st
, 2
nd
, 3
rd
, 10
th
,  
and 35
th
) from all patients. Ferro-kinetic studies (serum iron, serum ferritin, TIBC and transferrin saturation) 
were measured before and at the end of the study. Three groups were similar in terms of male/female ratio, age, 
height, weight, total blood volume, ASA classification, and baseline haemoglobin level. Group I included 5 male 
and 25 female patients, with mean age 68.43. Group II included 3 male and 28 female patients with mean age 
67.71. Group III included three male and 29 female patients with mean age 66.31. The primary variable which 
measured efficiency was the percentage of patients in each group requiring allogenic blood and the mean number 
of units given to each patient who received a transfusion. The secondary variable which measured efficiency was 
percentage of patients in each group who collected planned two units of autologous blood, the mean number of 
units collected per patients, and a change in haematological parameters.  
Statistical methods 
Demographic and analytical values were presented using descriptive statistics and expressed as mean±SD; 
medians, minimal and maximal observed values or percentage. The paired Student t-test was used to determine 
the significant differences within the group, and Wilcox test was used for data which values cannot be assumed 
to be normally distributed. The unpaired Student t-test and MannWhitney test were used to determine the 
statistical significance between the groups. A p value of less than 0.05 was considered as statistically significant. 
 
RESULTS 
Patients in Group I were able to collect 58 of the requested 60 units of autologous blood. Forty-nine of the 58 
units were transfused, and nine units were discarded. Patients in Group II were able to collect 61 of the requested 
62 units of autologous blood. Forty-three of the 61 unit were transfused, and eighteen units were discarded. 
Patients in Group III were able to collect 58 of the requested 64 units of autologous blood. Fifty of the 58 units 
transfused, and eight units were discarded. The effect of erythropoietic activity on haemoglobin level and 
reticulocytes count over time is shown in Figures 1 and 2. Only one patient in group II had haemoglobin level at 
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baseline less than, for autologous donation recommended 110 g/L (105. g/L), but because of effective 
stimulation of erythropoiesis, patient was able to donate one unit of autologous blood (at the time of first 
autologous blood donation haemoglobin level was 110 g/L). There were no significant differences among groups 
between postoperative haemoglobin levels. Mean reticulocyte count was not significantly different at initial 
assessment between all the groups. From 10
th
 preoperative day to the day of surgery, there was significant 
increase in reticulocyte count in both erythropoietin-treated groups. The reticulocyte count returned to baseline 
levels 5 weeks after surgery in all three groups. Six hours after surgery, and at the first postoperative day, 
patients who received erythropoietin (group I and II) had significantly higher values than did those in no-
erythropoietin group (III), p<0.001, t-test. Difference between reticulocytes count in Group I and II didn't reach 
significance during study period at any time. Intraoperative blood loss, postoperative reinfusion blood, blood 
loss in drains, and total blood loss are shown in Figure 3. The perioperative blood loss was similar among all 
groups.  
Transfusion 
The incidence of blood transfusion is shown in Figure 4. Only two patients in Group II did not receive blood 
transfusion. There were no patients who received allogenic blood transfusion intraoperatively. The highest 
proportion of patients who required blood transfusion intraoperatively (autologous) was in Group III, 16 (50%) 
patients compared with 7 (23,3%) and 4 (13.3%) patients in Group I and II, respectively, III:I,II p=0.0315, chi-
square test. There was no significant difference in postoperative consumption of autologous blood between 
groups. There were 34.4% of patients in group III exposed to allogenic blood transfusion postoperatively 
compared with 13.3% , and 6.4%  of patients in Group I and II, respectively, III:I,II p=0.013, III:II p=0<0.001, 
chi-square test . The difference in allogenic transfusion rates between Groups I and II (13.3% to 6.4%) did not 
reach significance (p=0.09, chi-square test). The mean number of blood units is shown in Figure 5. The mean 
number of units of allogenic blood transfused per patient was 0.23±0.49 (0-3), 0.13±0.51 (0-2), and 0.69±1.23 
(0-4) in Group I, II and III, respectively, III:I,II p=0.006, t-test. The mean number of total transfused units 
(autologous and allogenic) was 1.87±0.86 (0-5),  1.5±0.78 (0-4), and 2.25±1.24 (0-5), in Group I, II, and III, 
respectively, III: I, II p=0.013, t-test. There was no significant difference among the groups at baseline, as well at 
the end of study between serum iron, TIBC, ferritin and transferrin saturation. However, serum iron, ferritin and 
transferitin saturation at the end of study significantly decreased compared with baseline level, p<0.05, t-test for 
paired samples. 
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The use of erythropoietin in this study was generally well tolerated, with few adverse reactions which were 
nausea in four (6.5%), pyrexia in four (6.5%) and headache in three (4.9%) patients. The erythropoietin therapy 
was not discontinued in any patient because of these reactions. Postoperative complications included five wound 
hematomas (no operative evacuation was needed). 
 
DISCUSSION 
This study suggest that two, here compared, regimens of beta human recombinant erythropoietin intravenously 
(six-dose regimen vs. three-dose regimen, of the same weekly doses) for three weeks enabled collecting of two 
units of autologous blood and reduced allogenic blood transfusion in patients having THA. These results are in 
agreement with studies of Green et al. and Rosencher et al. [11,12]. Both, six-dose and three-dose regimen were 
associated with better haematological parameters on the day of surgery and lower overall requirement for 
transfusion of allogenic blood, when compared with no-erythropoietin treated group of patients. Previous major, 
double-blind, placebo controlled trials with daily regimen of rHuEpo for ten preoperative, and five postoperative 
days have shown benefit from rHuEpo in orthopaedic surgical patients by increasing total red cell mass of 
patients and reducing perioperative allogenic blood transfusion[13,14]. The trial by Goldberg et al demonstrated 
that weekly 600 IU/kg dosing regimen of rHuEpo was similar to the daily 300 IU/kg regimen, with respect to 
safety and the avoidance of allogenic transfusion in patients scheduled to undergo major orthopaedic 
arthroplasty[15]. After these trial weekly dose regimen was approved as the standard regimen for orthopaedic 
surgery. Contrary to this study, several trials demonstrated that more frequent administration could be more 
effective than less frequent one. Cody et al discussed that initial high peak level from high once weekly dose 
may be wasted as erythropoietin receptors on progenitor cells in bone marrow may become saturated; when 
these receptor are again free for binding, the level of serum erythropoietin will fall. Frequent administration of 
small amounts of rHuEpo could maintain a more constant low level, but effective level of serum 
erythropoietin[16]. Changes of reticulocytes count is one of powerful predictors of responsiveness to rHuEpo 
treatment[17,18]. In our study the mean reticulocytes count slightly increases, for several days, after the 
beginning of erythropoietin treatment, compared to baseline level, in both erythropoietin groups, and this results 
are consistent with the findings of Ramakrishnan et al.[19] They found that, after repeated erythropoietin 
administration, reticulocytes count steadily starts to rise until the peak level is reached after 200 to 300 hours. 
Then reticulocytes count starts declining to reach the baseline level. Non-erythropoietin treated patients received 
postoperatively allogenic blood transfusion at higher rate (34.4%) than patients who had twice weekly regimen 
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(13.3%), and once weekly regimen (6.4%). Although there was no significant difference between Groups I and II 
in percentage of allogenic blood transfusions, there was a slightly lower demand for allogenic blood transfusion 
in Group II (single weekly dose). The average consumption of transfused, overall blood (autologous and 
allogenic) were significantly higher (2.25±1.24 units/patient) compared with both erythropoietin treated groups. 
This results were in agreement with previous studies, which demonstrated that preoperative haemoglobin level 
was one of the strongest predictors of perioperative allogenic blood transfusion in perisurgical setting[20,21].  
Great proportion of authors have shown the superiority of subcutaneous route over intravenous for more 
sustained serum levels over time (12-18h) and lesser dose requirements[22-24].
 
But, subcutaneous injection can 
be painful and also nearly all patients who had antibody-mediated pure red cell aplasia, received erythropoietin 
administration by the subcutaneous route[25,26]. For this reason, and for short-term administration, Lee et 
al.[27] think that treatment by intravenous route is better for patients having autologous blood donation as it 
allows a more reliable serum level to be achieved and maintained. Several clinical studies[28]
 
analysed the 
relationship between erythropoietin, iron, and the erythropoietic response to anaemia. In our study relative weak 
response of erythropoiesis to 90 000 IU rHuEpo (approximately 6x200IU/kg or 3x400IU), could be explained 
with chosen doses of erythropoietin beta, and iron supplementation. Although all baseline iron parameters 
(including serum iron, TIBC and saturation of transferrin) were within the normal ranges, with no intergroup 
differences, iron stores are not sufficient, because the iron requirements exceed the available supply, during 
rHuEpo administration and accelerated erythropoiesis. Approximately 200 mg/d, (which was used in the current 
study) is a standard regimen of iron supplementation[17].  
 
Conclusion 
Although different dosing regimen of the same rHuEpo administration during  preoperative autologous blood 
donation have had similar effect on the collecting of two units of autologous blood, preoperative haemoglobin 
level and perioperative allogenic blood transfusion, once weekly dose regimen of rHuEpo was more convenient 
(although not statistically significant), and probably more comfortable for patients. With assumption that for the 
great proportion of patients it was more inconvenient, costly and psychologically and physically demanding if 
they had to visit hospital twice a week. For this reason we suggest more practical and comfortable but still very 
effective therapeutic regimen with single weekly intravenous administration of recombinant human 
erythropoietin (for patients scheduled for THA). 
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Figure 1. Haemoglobin values (means) during the study. 
Figure 2. Change in mean reticulocyte count from baseline during the study. 
Figure 3. Perioperative blood loss. 
Figure 4. The incidence of blood transfusion. 
Figure 5. The mean units collected/patient and transfused/patients. 
 
 
Table 1. The ferrokinetic studies.  
Data have shown as mean ±SD, and (minimal and maximal values) 
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